Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection

PHASE2CompletedINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

July 29, 2021

Primary Completion Date

March 25, 2024

Study Completion Date

May 1, 2024

Conditions
Enhanced Recovery After Surgery
Interventions
DRUG

TU-100

Treatment with investigational product

DRUG

Placebo

Treatment with placebo product

Trial Locations (36)

10065

New York Site, New York

11501

Mineola Site, Mineola

11794

Stony Brook Site, Stony Brook

15212

Pittsburgh Site, Pittsburgh

19140

Philadelphia Site #2, Philadelphia

24014

Roanoke Site, Roanoke

29425

Charleston Site, Charleston

32803

Orlando Site, Orlando

33331

Weston Site, Weston

33606

Tampa Site, Tampa

33756

Clearwater Site, Clearwater

35630

Florence Site, Florence

38120

Memphis Site, Memphis

40536

Lexington Site, Lexington

44111

Cleveland Site #2, Cleveland

44195

Cleveland Site #1, Cleveland

48201

Detroit Site, Detroit

53226

Milwaukee Site, Milwaukee

60612

Chicago Site #2, Chicago

60637

Chicago Site #1, Chicago

61801

Urbana Site, Urbana

63110

St. Louis Site, St Louis

70006

Metairie Site, Metairie

72205

Little Rock Site, Little Rock

75246

Dallas Site, Dallas

76104

Fort Worth Site, Fort Worth

84132

Salt Lake City Site, Salt Lake City

85234

Gilbert Site, Gilbert

90033

Los Angeles Site #1, Los Angeles

90048

Los Angeles Site #2, Los Angeles

91010

Duarte Site, Duarte

94304

Palo Alto Site, Palo Alto

95817

Sacramento Site, Sacramento

06810

Danbury Site, Danbury

02115

Boston Site #1, Boston

07103

Newark Site, Newark

All Listed Sponsors
lead

Tsumura USA

INDUSTRY

NCT04742907 - Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection | Biotech Hunter | Biotech Hunter